Compare Ascendis Pharma A/S (ASND) vs United States Brent Oil Fund LP (BNO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs United States Brent Oil Fund LP — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while United States Brent Oil Fund LP trades at $43.58. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| ASND | BNO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Energy |
52-Week High | $277.18 | $60.13 |
52-Week Low | $163.32 | $27.20 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BNO trades at $42.15, showing minimal daily movement with a slight 0.05% decline. Technical indicators present a neutral to bearish picture with mixed signals from moving averages and oscillators. Recent news highlights oil price volatility driven by Middle East tensions, with WTI crude experiencing significant swings. The stock currently trades near its pivot point of $42, with immediate support at $42 and resistance at $43.
The outlook remains cautious as geopolitical risks and oil market volatility create uncertainty. While strategic oil reserve buying through 2028 may provide demand support, concerns about China's oil demand recovery and potential market surpluses present headwinds. The neutral technical stance suggests waiting for clearer directional momentum before establishing significant positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →
